(QGEN) Qiagen - Overview
Exchange: NYSE •
Country: Netherlands •
Currency: USD •
Type: Common Stock •
ISIN: NL0015002CX3
Stock: Diagnostics, Research Tools, Software, Services
Total Rating 50
Risk 89
Buy Signal -0.43
| Risk 5d forecast | |
|---|---|
| Volatility | 29.5% |
| Relative Tail Risk | -7.73% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.32 |
| Alpha | -2.24 |
| Character TTM | |
|---|---|
| Beta | 0.512 |
| Beta Downside | -0.228 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.06% |
| CAGR/Max DD | -0.03 |
EPS (Earnings per Share)
Revenue
Description: QGEN Qiagen March 04, 2026
Qiagen N.V. (QGEN) offers sample to insight solutions, converting biological samples into molecular data. This involves a multi-stage process from sample collection to data analysis.
The companys product portfolio includes consumables for nucleic acid stabilization and purification, essential for genetic analysis across various applications. It also provides instruments for automated sample processing and quality control, a common component in life science research.
QGEN develops assays for immune response, oncology, and reproductive health. These diagnostic tools are critical in molecular diagnostics, a growing sector focused on identifying diseases at a molecular level.
The company also supplies PCR consumables and instruments, fundamental tools in molecular biology for DNA amplification. Additionally, QGEN offers next-generation sequencing (NGS) products, bioinformatics solutions, and laboratory services, reflecting the increasing demand for high-throughput genomic analysis.
QGEN serves diverse markets, including molecular diagnostics, academia, pharmaceuticals, and applied testing. For a detailed breakdown of their market penetration and product performance, further research on ValueRay is recommended.
Headlines to watch out for
- Diagnostic test kit sales drive revenue growth
- Research consumables demand impacts sales
- Regulatory approvals influence product launches
- Competition in molecular diagnostics affects market share
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 424.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.64 > 1.0 |
| NWC/Revenue: 70.95% < 20% (prev 71.59%; Δ -0.64% < -1%) |
| CFO/TA 0.10 > 3% & CFO 654.3m > Net Income 424.9m |
| Net Debt (815.4m) to EBITDA (717.3m): 1.14 < 3 |
| Current Ratio: 3.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (207.8m) vs 12m ago -4.70% < -2% |
| Gross Margin: 61.79% > 18% (prev 0.49%; Δ 6.13k% > 0.5%) |
| Asset Turnover: 34.88% > 50% (prev 34.77%; Δ 0.11% > 0%) |
| Interest Coverage Ratio: 15.74 > 6 (EBITDA TTM 717.3m / Interest Expense TTM 33.3m) |
Altman Z'' 4.55
| A: 0.24 (Total Current Assets 2.00b - Total Current Liabilities 512.1m) / Total Assets 6.30b |
| B: 0.44 (Retained Earnings 2.75b / Total Assets 6.30b) |
| C: 0.09 (EBIT TTM 523.5m / Avg Total Assets 5.99b) |
| D: 0.94 (Book Value of Equity 2.37b / Total Liabilities 2.52b) |
| Altman-Z'' Score: 4.55 = AA |
Beneish M -3.34
| DSRI: 0.83 (Receivables 402.6m/459.0m, Revenue 2.09b/1.98b) |
| GMI: 0.79 (GM 61.79% / 48.90%) |
| AQI: 1.03 (AQ_t 0.54 / AQ_t-1 0.52) |
| SGI: 1.06 (Revenue 2.09b / 1.98b) |
| TATA: -0.04 (NI 424.9m - CFO 654.3m) / TA 6.30b) |
| Beneish M-Score: -3.34 (Cap -4..+1) = AA |
What is the price of QGEN shares?
As of March 17, 2026, the stock is trading at USD 40.92 with a total of 1,686,844 shares traded.
Over the past week, the price has changed by -5.56%, over one month by -16.08%, over three months by -4.21% and over the past year by +8.84%.
Over the past week, the price has changed by -5.56%, over one month by -16.08%, over three months by -4.21% and over the past year by +8.84%.
Is QGEN a buy, sell or hold?
Qiagen has received a consensus analysts rating of 3.94.
Therefore, it is recommended to buy QGEN.
- StrongBuy: 6
- Buy: 3
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the QGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.2 | 35% |
| Analysts Target Price | 55.2 | 35% |
QGEN Fundamental Data Overview March 15, 2026
P/E Trailing = 19.902
P/E Forward = 14.0449
P/S = 4.0032
P/B = 2.2428
P/EG = 1.1233
Revenue TTM = 2.09b USD
EBIT TTM = 523.5m USD
EBITDA TTM = 717.3m USD
Long Term Debt = 1.63b USD (from longTermDebt, two quarters ago)
Short Term Debt = 499.6m USD (from shortTermDebt, two quarters ago)
Debt = 1.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 815.4m USD (from netDebt column, last quarter)
Enterprise Value = 8.92b USD (8.37b + Debt 1.65b - CCE 1.10b)
Interest Coverage Ratio = 15.74 (Ebit TTM 523.5m / Interest Expense TTM 33.3m)
EV/FCF = 19.71x (Enterprise Value 8.92b / FCF TTM 452.6m)
FCF Yield = 5.07% (FCF TTM 452.6m / Enterprise Value 8.92b)
FCF Margin = 21.66% (FCF TTM 452.6m / Revenue TTM 2.09b)
Net Margin = 20.33% (Net Income TTM 424.9m / Revenue TTM 2.09b)
Gross Margin = 61.79% ((Revenue TTM 2.09b - Cost of Revenue TTM 798.5m) / Revenue TTM)
Gross Margin QoQ = 58.71% (prev 62.20%)
Tobins Q-Ratio = 1.42 (Enterprise Value 8.92b / Total Assets 6.30b)
Interest Expense / Debt = 0.61% (Interest Expense 10.1m / Debt 1.65b)
Taxrate = 1.23% (1.34m / 109.2m)
NOPAT = 517.1m (EBIT 523.5m * (1 - 1.23%))
Current Ratio = 3.90 (Total Current Assets 2.00b / Total Current Liabilities 512.1m)
Debt / Equity = 0.44 (Debt 1.65b / totalStockholderEquity, last quarter 3.78b)
Debt / EBITDA = 1.14 (Net Debt 815.4m / EBITDA 717.3m)
Debt / FCF = 1.80 (Net Debt 815.4m / FCF TTM 452.6m)
Total Stockholder Equity = 3.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 424.9m / Total Assets 6.30b)
RoE = 11.85% (Net Income TTM 424.9m / Total Stockholder Equity 3.59b)
RoCE = 10.04% (EBIT 523.5m / Capital Employed (Equity 3.59b + L.T.Debt 1.63b))
RoIC = 9.98% (NOPAT 517.1m / Invested Capital 5.18b)
WACC = 6.61% (E(8.37b)/V(10.02b) * Re(7.80%) + D(1.65b)/V(10.02b) * Rd(0.61%) * (1-Tc(0.01)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.65%
[DCF] Terminal Value 83.18% ; FCFF base≈472.5m ; Y1≈462.8m ; Y5≈470.0m
[DCF] Fair Price = 51.24 (EV 11.37b - Net Debt 815.4m = Equity 10.56b / Shares 206.0m; r=6.61% [WACC]; 5y FCF grow -3.02% → 2.90% )
EPS Correlation: -4.17 | EPS CAGR: -9.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: -7.44 | Revenue CAGR: -3.94% | SUE: 3.22 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.62 | Chg7d=-0.000 | Chg30d=-0.056 | Revisions Net=-6 | Analysts=11
EPS current Year (2026-12-31): EPS=2.51 | Chg7d=+0.000 | Chg30d=+0.001 | Revisions Net=-11 | Growth EPS=+5.5% | Growth Revenue=+6.0%
EPS next Year (2027-12-31): EPS=2.76 | Chg7d=+0.000 | Chg30d=-0.036 | Revisions Net=-6 | Growth EPS=+10.1% | Growth Revenue=+5.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.9% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = +1.1% (Analyst 4.0% - Implied 2.9%)
P/E Forward = 14.0449
P/S = 4.0032
P/B = 2.2428
P/EG = 1.1233
Revenue TTM = 2.09b USD
EBIT TTM = 523.5m USD
EBITDA TTM = 717.3m USD
Long Term Debt = 1.63b USD (from longTermDebt, two quarters ago)
Short Term Debt = 499.6m USD (from shortTermDebt, two quarters ago)
Debt = 1.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 815.4m USD (from netDebt column, last quarter)
Enterprise Value = 8.92b USD (8.37b + Debt 1.65b - CCE 1.10b)
Interest Coverage Ratio = 15.74 (Ebit TTM 523.5m / Interest Expense TTM 33.3m)
EV/FCF = 19.71x (Enterprise Value 8.92b / FCF TTM 452.6m)
FCF Yield = 5.07% (FCF TTM 452.6m / Enterprise Value 8.92b)
FCF Margin = 21.66% (FCF TTM 452.6m / Revenue TTM 2.09b)
Net Margin = 20.33% (Net Income TTM 424.9m / Revenue TTM 2.09b)
Gross Margin = 61.79% ((Revenue TTM 2.09b - Cost of Revenue TTM 798.5m) / Revenue TTM)
Gross Margin QoQ = 58.71% (prev 62.20%)
Tobins Q-Ratio = 1.42 (Enterprise Value 8.92b / Total Assets 6.30b)
Interest Expense / Debt = 0.61% (Interest Expense 10.1m / Debt 1.65b)
Taxrate = 1.23% (1.34m / 109.2m)
NOPAT = 517.1m (EBIT 523.5m * (1 - 1.23%))
Current Ratio = 3.90 (Total Current Assets 2.00b / Total Current Liabilities 512.1m)
Debt / Equity = 0.44 (Debt 1.65b / totalStockholderEquity, last quarter 3.78b)
Debt / EBITDA = 1.14 (Net Debt 815.4m / EBITDA 717.3m)
Debt / FCF = 1.80 (Net Debt 815.4m / FCF TTM 452.6m)
Total Stockholder Equity = 3.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 424.9m / Total Assets 6.30b)
RoE = 11.85% (Net Income TTM 424.9m / Total Stockholder Equity 3.59b)
RoCE = 10.04% (EBIT 523.5m / Capital Employed (Equity 3.59b + L.T.Debt 1.63b))
RoIC = 9.98% (NOPAT 517.1m / Invested Capital 5.18b)
WACC = 6.61% (E(8.37b)/V(10.02b) * Re(7.80%) + D(1.65b)/V(10.02b) * Rd(0.61%) * (1-Tc(0.01)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.65%
[DCF] Terminal Value 83.18% ; FCFF base≈472.5m ; Y1≈462.8m ; Y5≈470.0m
[DCF] Fair Price = 51.24 (EV 11.37b - Net Debt 815.4m = Equity 10.56b / Shares 206.0m; r=6.61% [WACC]; 5y FCF grow -3.02% → 2.90% )
EPS Correlation: -4.17 | EPS CAGR: -9.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: -7.44 | Revenue CAGR: -3.94% | SUE: 3.22 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.62 | Chg7d=-0.000 | Chg30d=-0.056 | Revisions Net=-6 | Analysts=11
EPS current Year (2026-12-31): EPS=2.51 | Chg7d=+0.000 | Chg30d=+0.001 | Revisions Net=-11 | Growth EPS=+5.5% | Growth Revenue=+6.0%
EPS next Year (2027-12-31): EPS=2.76 | Chg7d=+0.000 | Chg30d=-0.036 | Revisions Net=-6 | Growth EPS=+10.1% | Growth Revenue=+5.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.9% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = +1.1% (Analyst 4.0% - Implied 2.9%)